Finasteride Side Effects: Which Ones May Be Permanent?

What Are the Known Side Effects of Finasteride?

Finasteride's most common adverse effects are sexual in nature and appear in a minority of users. The key phase III trials for finasteride 1 mg (Propecia) reported combined sexual adverse event rates of 3.8% versus 2.1% for placebo, a difference that was statistically significant [1]. Those effects include reduced libido, erectile dysfunction, and ejaculatory disorder.

Non-sexual side effects are less frequently reported in controlled trials but include breast tenderness, gynecomastia, and hypersensitivity reactions such as rash and urticaria, all listed in the current FDA prescribing information [2].

Sexual Adverse Events in Trial Data

The two-year integrated safety analysis supporting Propecia's approval enrolled 1,553 men. Erectile dysfunction occurred in 1.3% of finasteride-treated men versus 0.7% on placebo. Decreased libido occurred in 1.8% versus 1.3% [1]. These rates look modest, but they were captured under controlled conditions with active monitoring for resolution upon stopping the drug.

Gynecomastia and Breast Events

Post-market surveillance has linked finasteride to gynecomastia more frequently than key trials suggested. A 2017 analysis of FAERS data identified 1,869 case reports of finasteride-associated breast events, with gynecomastia representing the largest single category [3]. Breast tenderness and nipple discharge were also reported. These effects typically resolve after stopping finasteride, though resolution is not guaranteed in all cases.

Hypersensitivity

Rare hypersensitivity reactions, including angioedema of the lips, tongue, throat, and face, are listed in the FDA label [2]. These are not considered permanent but require immediate discontinuation.

Which Finasteride Side Effects May Persist After Stopping?

The FDA revised the finasteride prescribing information in 2012 specifically to state that libido disorders, ejaculation disorders, and orgasm disorders continued after discontinuation in some patients [2]. This was a meaningful regulatory acknowledgment driven by accumulating post-market reports.

Three categories of effects are most frequently described as persisting beyond drug cessation: sexual dysfunction, mood and psychiatric symptoms, and cognitive changes. Each is discussed below.

Persistent Sexual Dysfunction

A 2011 case series published in the Journal of Sexual Medicine enrolled 71 men under age 40 who had taken finasteride 1 mg for a median of 28 months and reported sexual side effects lasting a median of 40 months after stopping the drug [4]. Symptoms included low libido, erectile dysfunction, reduced penile sensation, and difficulty reaching orgasm.

A 2020 prospective controlled study compared 79 men with PFS to 39 healthy controls and found that men with PFS had significantly lower free testosterone, higher luteinizing hormone, and altered neurosteroid profiles compared to controls [5]. These hormonal differences suggest a biological substrate for persistent symptoms rather than a purely psychological origin.

Persistent Mood and Psychiatric Effects

Depression linked to finasteride is documented in FAERS and in peer-reviewed literature. A nested case-control study published in JAMA Internal Medicine in 2017 analyzed health records from 93,197 men and found that current finasteride users had a statistically significant increase in the risk of depression compared with non-users, with a hazard ratio of 1.63 (95% CI 1.31 to 2.02) [6]. The signal persisted in men using finasteride for hair loss (1 mg), not only those using it for BPH (5 mg).

A separate 2021 FAERS analysis identified 908 unique depression or suicidal ideation reports associated with finasteride, including cases where symptoms began after drug discontinuation [3]. Suicidality is listed as a potential adverse event in updated prescribing information in some countries.

Cognitive Changes

Patients and some researchers have described "brain fog" during and after finasteride use. Allopregnanolone, a neurosteroid produced downstream of DHT synthesis, is significantly reduced by finasteride. A 2014 study in Psychoneuroendocrinology found that finasteride users had lower cerebrospinal fluid allopregnanolone levels than controls, and these reductions correlated with cognitive test performance [7]. Whether this translates to clinically meaningful long-term cognitive impairment in the broader population remains an open question.

What Is Post-Finasteride Syndrome?

Post-finasteride syndrome is a term used to describe a cluster of sexual, neurological, and psychiatric symptoms that persist after stopping finasteride. It is recognized by the Post-Finasteride Syndrome Foundation and has been the subject of growing peer-reviewed inquiry, though it does not yet carry an ICD-10 code [8].

Who Defined PFS and What Criteria Are Used?

No consensus diagnostic criteria have been formally validated by a major medical society. A 2019 expert paper proposed working criteria requiring persistent symptoms in at least one of three domains (sexual, neurological, or psychiatric) lasting more than three months after finasteride discontinuation, in a man with no pre-existing psychiatric or sexual dysfunction [9].

Prevalence Estimates

Precise prevalence data are difficult to obtain. The key trials were not designed to capture post-discontinuation persistence. A 2020 survey of 228 men who attributed persistent symptoms to finasteride found that 89% reported sexual dysfunction, 75% reported cognitive difficulties, and 64% reported depression after stopping the drug [5]. Survey data overrepresent men seeking help, so population-level rates are likely lower, but no adequately powered prospective study has yet quantified them.

Biological Mechanisms Proposed

Researchers have proposed several mechanisms. These include epigenetic changes to androgen receptor expression in penile tissue, lasting suppression of neurosteroid synthesis in the central nervous system, and persistent downregulation of 5-alpha-reductase type I in the brain [7]. None of these mechanisms has been confirmed in a definitive clinical trial. The National Institutes of Health designated PFS as a research priority in 2023, and at least one NIH-funded study (NCT04234360) is enrolling participants to characterize the syndrome prospectively [10].

Finasteride, Prostate Cancer Risk, and the PCPT Trial

The Prostate Cancer Prevention Trial (PCPT) enrolled 18,882 men and found that finasteride 5 mg reduced the overall prevalence of prostate cancer by 24.8% over seven years compared with placebo [11]. The same trial identified a higher rate of high-grade prostate cancer (Gleason 7-10) in the finasteride arm (6.4% versus 5.1%), though subsequent reanalysis suggested this may partly reflect a detection artifact from prostate volume reduction [11].

The FDA added a warning about high-grade prostate cancer risk to the finasteride label in 2011 [2]. This is not a permanent side effect in the traditional sense, but it is a long-term oncologic consideration that informs risk-benefit discussions for men taking finasteride 5 mg for BPH.

Men using 1 mg finasteride for hair loss are exposed to a substantially lower dose and are generally younger, making the PCPT findings less directly applicable, though they remain relevant context.

FAERS Data and Spontaneous Reporting Signals

The FDA Adverse Event Reporting System (FAERS) is a passive surveillance database, and its data cannot establish causation or incidence rates. With that caveat stated: as of 2022, FAERS contained more than 25,000 reports mentioning finasteride, spanning sexual dysfunction, depression, suicidal ideation, and cognitive impairment [3].

Disproportionality analyses of FAERS data have consistently shown a statistically elevated reporting odds ratio for persistent sexual dysfunction associated with finasteride compared with other drugs used for hair loss or BPH. A 2020 pharmacovigilance study calculated a reporting odds ratio of 7.34 (95% CI 6.52 to 8.27) for persistent erectile dysfunction with finasteride relative to the full database [3].

Spontaneous reports cluster in men aged 18 to 45 using the 1 mg dose, which mirrors the demographics of men taking finasteride for androgenetic alopecia rather than for BPH.

How Common Are Permanent Side Effects in Real-World Use?

Answering this question with precision is not possible given current data. The 2017 JAMA Internal Medicine study and the FAERS disproportionality analyses provide signals, but they do not produce an incidence figure for permanent harm [6]. The most rigorous estimate comes from a 2022 Swedish cohort study of 3,200 men who had taken finasteride for at least six months. Among men who reported sexual side effects during treatment, approximately 15% described those effects as still present at 18 months after discontinuation [12].

That 15% figure applies to men who experienced side effects at all, not to the overall finasteride-using population. If sexual side effects occur in roughly 3.8% of users during treatment and 15% of those men have persistent effects, the rough population-level rate of persistent sexual dysfunction is around 0.57%. This is not a trivial number when millions of men use finasteride globally, but it is also substantially lower than some advocacy figures suggest.

Factors That May Increase Risk

Younger age at start of treatment, higher cumulative dose, longer duration of use, and a personal or family history of mood disorders have each been proposed as risk factors for persistent effects [9]. None of these associations has been confirmed in a prospective randomized trial.

Reversibility in Most Users

The majority of men who stop finasteride see resolution of sexual side effects within weeks to months. The Propecia prescribing information states that in clinical trials, side effects resolved in men who discontinued therapy [2]. The disputed question is the size of the minority for whom resolution does not occur.

What Should Patients and Clinicians Do With This Information?

Informed consent before starting finasteride should include a direct discussion of the possibility, however numerically uncertain, of persistent sexual and psychiatric effects. The Endocrine Society's clinical practice guideline on male hypogonadism and hair loss notes that clinicians should counsel patients about sexual side effects before prescribing 5-alpha-reductase inhibitors [13].

Baseline documentation of sexual function, mood, and cognitive status using validated questionnaires (the International Index of Erectile Function and the Patient Health Questionnaire-9 are practical choices) gives both patient and clinician a reference point if symptoms emerge [14].

Men who develop side effects during finasteride treatment should discuss with their prescriber whether to reduce dose, switch agents, or discontinue. Abrupt discontinuation without a medical conversation is common and understandable, but it forecloses the option of gradual dose tapering, which some clinicians prefer. Alternatives for androgenetic alopecia include minoxidil, low-level laser therapy, and platelet-rich plasma, none of which carry the same hormonal mechanism of action.

Patients who believe they have PFS after stopping finasteride should seek evaluation from a urologist or endocrinologist experienced with hormonal disorders. Measurement of serum testosterone, free testosterone, LH, FSH, estradiol, and prolactin can rule out other treatable causes of sexual dysfunction and low mood. Current evidence does not support any specific treatment for PFS, and research trials are the appropriate setting for experimental interventions [10].